Cargando…
Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial
BACKGROUND: COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560/ https://www.ncbi.nlm.nih.gov/pubmed/34426106 http://dx.doi.org/10.1016/j.intimp.2021.107961 |
_version_ | 1783718832851910656 |
---|---|
author | Fakharian, Atefeh Barati, Saghar Mirenayat, Maryam Rezaei, Mitra Haseli, Sara Torkaman, Pooria Yousefian, Sahar Dastan, Alireza jamaati, Hamidreza Dastan, Farzaneh |
author_facet | Fakharian, Atefeh Barati, Saghar Mirenayat, Maryam Rezaei, Mitra Haseli, Sara Torkaman, Pooria Yousefian, Sahar Dastan, Alireza jamaati, Hamidreza Dastan, Farzaneh |
author_sort | Fakharian, Atefeh |
collection | PubMed |
description | BACKGROUND: COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To this end, in order to manage pneumonia caused by COVID-19, adalimumab may potentially be considered as a potential therapeutic agent. The present study aimed to investigate the potential therapeutic role of adalimumab in treating COVID-19 cases in combination therapy with remdesivir and dexamethasone. METHODS: Among the 68 patients who were included in the current randomized controlled trial, 34 were assigned to the adalimumab group and the remaining 34 were assigned to the control group. Adalimumab at a dose of 40 mg, subcutaneous for once, was used for the intervention group. Both the intervention and control groups received remdesivir, dexamethasone, and supportive care. The data gathered to make comparisons of the groups included demographic information, the rate of mortality, mechanical ventilation requirement, length of stay in hospital and Intensive Care Unit (ICU), and imaging findings. RESULTS: There was no significant difference between the two groups in the terms of mortality rate (P-value = 1) and mechanical ventilation requirement (P-value = 1). The length of hospital and ICU stay as well as radiologic changes were not affected either (P-value = 1, 0.27, and 0.53, respectively). CONCLUSIONS: Our findings did not support the use of adalimumab in combination with remdesivir and dexamethasone in the treatment of severe COVID-19 cases. |
format | Online Article Text |
id | pubmed-8260560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82605602021-07-07 Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial Fakharian, Atefeh Barati, Saghar Mirenayat, Maryam Rezaei, Mitra Haseli, Sara Torkaman, Pooria Yousefian, Sahar Dastan, Alireza jamaati, Hamidreza Dastan, Farzaneh Int Immunopharmacol Article BACKGROUND: COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To this end, in order to manage pneumonia caused by COVID-19, adalimumab may potentially be considered as a potential therapeutic agent. The present study aimed to investigate the potential therapeutic role of adalimumab in treating COVID-19 cases in combination therapy with remdesivir and dexamethasone. METHODS: Among the 68 patients who were included in the current randomized controlled trial, 34 were assigned to the adalimumab group and the remaining 34 were assigned to the control group. Adalimumab at a dose of 40 mg, subcutaneous for once, was used for the intervention group. Both the intervention and control groups received remdesivir, dexamethasone, and supportive care. The data gathered to make comparisons of the groups included demographic information, the rate of mortality, mechanical ventilation requirement, length of stay in hospital and Intensive Care Unit (ICU), and imaging findings. RESULTS: There was no significant difference between the two groups in the terms of mortality rate (P-value = 1) and mechanical ventilation requirement (P-value = 1). The length of hospital and ICU stay as well as radiologic changes were not affected either (P-value = 1, 0.27, and 0.53, respectively). CONCLUSIONS: Our findings did not support the use of adalimumab in combination with remdesivir and dexamethasone in the treatment of severe COVID-19 cases. Elsevier B.V. 2021-10 2021-07-07 /pmc/articles/PMC8260560/ /pubmed/34426106 http://dx.doi.org/10.1016/j.intimp.2021.107961 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Fakharian, Atefeh Barati, Saghar Mirenayat, Maryam Rezaei, Mitra Haseli, Sara Torkaman, Pooria Yousefian, Sahar Dastan, Alireza jamaati, Hamidreza Dastan, Farzaneh Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title_full | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title_fullStr | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title_full_unstemmed | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title_short | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
title_sort | evaluation of adalimumab effects in managing severe cases of covid-19: a randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560/ https://www.ncbi.nlm.nih.gov/pubmed/34426106 http://dx.doi.org/10.1016/j.intimp.2021.107961 |
work_keys_str_mv | AT fakharianatefeh evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT baratisaghar evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT mirenayatmaryam evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT rezaeimitra evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT haselisara evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT torkamanpooria evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT yousefiansahar evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT dastanalireza evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT jamaatihamidreza evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial AT dastanfarzaneh evaluationofadalimumabeffectsinmanagingseverecasesofcovid19arandomizedcontrolledtrial |